Vanderbilt Vaccine Center Archives
AstraZeneca VP to discuss COVID-19 collaboration with VUMC Nov. 17
Nov. 10, 2022—On Thursday, Nov. 17, Mark Esser, PhD, vice president, Early Vaccines and Immune Therapies R&D at AstraZeneca, will discuss his company’s collaboration with Vanderbilt University Medical Center that led to development of the Evusheld antibody combo to prevent COVID-19 in high-risk individuals.
Study finds Moderna’s COVID-19 vaccine safe and effective for young children
Nov. 4, 2022—A Vanderbilt study finds that Moderna’s COVID-19 vaccine is safe and effective in children 6 months to 5 years of age.
Event to spotlight VUMC’s COVID-19 research efforts
Nov. 3, 2022—The public is invited to listen in as scientists on the forefront of COVID-19 research at Vanderbilt University Medical Center share their personal stories on Wednesday afternoon, Nov. 16, in 214 Light Hall.
Vanderbilt’s Crowe receives the Building the Foundation Award from Research!America
Oct. 6, 2022—Vanderbilt's James Crowe Jr., MD, has received the Building the Foundation Award from Research!America, a national biomedical research advocacy organization.
COVID antibody research conducted at VUMC lands national award
Aug. 24, 2022—A long-acting antibody combination discovered at Vanderbilt University Medical Center that protects against COVID-19 in high-risk individuals has received a gold medal in the 2022 R&D 100 awards program announced Aug. 22 by R&D World Magazine.
Darling honored by Society of Research Administrators
Jul. 14, 2022—Vanderbilt's Heather Darling, PMP, has been selected as a Future of the Field honoree by the Society of Research Administrators International.
Crowe receives national award for COVID antibody research
Mar. 31, 2022—Vanderbilt's James Crowe Jr., MD, and Michel Nussenzweig, MD, PhD, of The Rockefeller University, have been jointly awarded the 2022 Harrington Prize for Innovation in Medicine for “groundbreaking work” that enabled the use of human antibodies to treat COVID-19.
Technique hastens COVID-19 antibody discovery
Mar. 10, 2022—Optimization of a technique developed at Vanderbilt University Medical Center enables rapid and efficient identification of neutralizing monoclonal antibodies against the virus that causes COVID-19.
Research Staff Awards honor those who help drive science forward
Mar. 9, 2022—Laboratory and administrative personnel at Vanderbilt University Medical Center were honored March 4 for research excellence during the 18th annual Research Staff Awards Ceremony.
Pandemic leads to broader use of monoclonal antibodies
Feb. 17, 2022—Antiviral drugs and coronavirus-fighting monoclonal antibodies, including those discovered at Vanderbilt University Medical Center, remain crucially important in the continuing fight against COVID-19.
Patient receives antibodies discovered at Vanderbilt to prevent COVID-19 illness
Dec. 23, 2021—On Dec. 22, Caroline Davis of Nashville became the first patient at Vanderbilt University Medical Center to receive injections of a new antibody combination to protect her from COVID-19.
Antibodies discovered at Vanderbilt for prevention of COVID-19 granted FDA emergency use authorization
Dec. 9, 2021—The U.S. Food and Drug Administration granted emergency use authorization (EUA) to the global biopharmaceutical company AstraZeneca for a long-acting antibody combination which protects against COVID-19, discovered last year at Vanderbilt University Medical Center.
